Treatment of Inoperable Stage III or Stage IV (Metastatic) Merkel Cell Carcinoma
This protocol addresses patients with Merkel cell carcinoma that is no longer surgically resectable at stage III, or has progressed to distant metastatic disease at stage IV. Despite advances in diagnosis and treatment, inoperable stage III and IV Merkel cell carcinoma remain incurable, making careful selection of the treatment strategy essential.
Clinical scenario
Patients with inoperable stage III or stage IV (metastatic) Merkel cell carcinoma where the disease is not amenable to curative surgery. The goal is disease control and preservation of quality of life, with management decisions guided by performance status, prior treatment history, and individual patient factors.
Treatment approach — partial overview
When immunotherapy is not an option or has been exhausted, management centres on systemic and locoregional palliative modalities alongside best supportive care. Enrolment in a clinical trial is the preferred pathway where available.
The complete protocol — specific agents, sequencing criteria, fractionation schedules, and performance-status–adapted recommendations — is available in the full structured regimen below.
References
- Despite the recent advances in diagnosis and treatment, inoperable stage III and IV MCC remain incurable.
- In patients with contraindications or after failure of immunotherapy, palliative RT and/or ChT may be options, but their impact on OS is uncertain.
- ChT regimens that have been used to treat patients with MCC include taxanes, topotecan, a combination of etoposide-cisplatin, etoposide-carboplatin or cyclophosphamide-doxorubicin-vincristine.
- Patients of poor performance status should be considered for a lower dose hypofractionation schedule (e.g. 20 Gy in 5 fractions or 30 Gy in 10 fractions), which can still achieve tumour regression.
DOI: 10.1016/j.esmoop.2024.102977
View source ↗